345 related articles for article (PubMed ID: 18835164)
1. 'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5456-9. PubMed ID: 18835164
[TBL] [Abstract][Full Text] [Related]
2. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
3. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
[TBL] [Abstract][Full Text] [Related]
4. Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Kucharski J; Lum C; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Urban J; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2010 Aug; 20(16):4819-24. PubMed ID: 20663667
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
Cogan DA; Aungst R; Breinlinger EC; Fadra T; Goldberg DR; Hao MH; Kroe R; Moss N; Pargellis C; Qian KC; Swinamer AD
Bioorg Med Chem Lett; 2008 Jun; 18(11):3251-5. PubMed ID: 18462940
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of unactivated p38 MAP kinase.
Bullington J; Argentieri D; Averill K; Carter D; Cavender D; Fahmy B; Fan X; Hall D; Heintzelman G; Jackson P; Leung WP; Li X; Ling P; Olini G; Razler T; Reuman M; Rupert K; Russell R; Siekierka J; Wadsworth S; Wolff R; Xiang B; Zhang YM
Bioorg Med Chem Lett; 2006 Dec; 16(23):6102-6. PubMed ID: 16971122
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.
McClure KF; Letavic MA; Kalgutkar AS; Gabel CA; Audoly L; Barberia JT; Braganza JF; Carter D; Carty TJ; Cortina SR; Dombroski MA; Donahue KM; Elliott NC; Gibbons CP; Jordan CK; Kuperman AV; Labasi JM; Laliberte RE; McCoy JM; Naiman BM; Nelson KL; Nguyen HT; Peese KM; Sweeney FJ; Taylor TJ; Trebino CE; Abramov YA; Laird ER; Volberg WA; Zhou J; Bach J; Lombardo F
Bioorg Med Chem Lett; 2006 Aug; 16(16):4339-44. PubMed ID: 16759861
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
Park H; Bahn YJ; Jeong DG; Woo EJ; Kwon JS; Ryu SE
Bioorg Med Chem Lett; 2008 Oct; 18(20):5372-6. PubMed ID: 18835158
[TBL] [Abstract][Full Text] [Related]
11. p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design.
Natarajan SR; Heller ST; Nam K; Singh SB; Scapin G; Patel S; Thompson JE; Fitzgerald CE; O'Keefe SJ
Bioorg Med Chem Lett; 2006 Nov; 16(22):5809-13. PubMed ID: 16945533
[TBL] [Abstract][Full Text] [Related]
12. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
[TBL] [Abstract][Full Text] [Related]
13. Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors.
Orvieto F; Branca D; Giomini C; Jones P; Koch U; Ontoria JM; Palumbi MC; Rowley M; Toniatti C; Muraglia E
Bioorg Med Chem Lett; 2009 Aug; 19(15):4196-200. PubMed ID: 19541484
[TBL] [Abstract][Full Text] [Related]
14. Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.
Hammach A; Barbosa A; Gaenzler FC; Fadra T; Goldberg D; Hao MH; Kroe RR; Liu P; Qian KC; Ralph M; Sarko C; Soleymanzadeh F; Moss N
Bioorg Med Chem Lett; 2006 Dec; 16(24):6316-20. PubMed ID: 17010605
[TBL] [Abstract][Full Text] [Related]
15. Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules.
Luedtke GR; Schinzel K; Tan X; Tester RW; Nashashibi I; Xu YJ; Dugar S; Levy DE; Jung J
Bioorg Med Chem Lett; 2010 Apr; 20(8):2556-9. PubMed ID: 20346653
[TBL] [Abstract][Full Text] [Related]
16. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
[TBL] [Abstract][Full Text] [Related]
17. Indole RSK inhibitors. Part 1: discovery and initial SAR.
Boyer SJ; Burke J; Guo X; Kirrane TM; Snow RJ; Zhang Y; Sarko C; Soleymanzadeh L; Swinamer A; Westbrook J; Dicapua F; Padyana A; Cogan D; Gao A; Xiong Z; Madwed JB; Kashem M; Kugler S; O'Neill MM
Bioorg Med Chem Lett; 2012 Jan; 22(1):733-7. PubMed ID: 22100312
[TBL] [Abstract][Full Text] [Related]
18. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
[TBL] [Abstract][Full Text] [Related]
19. Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.
Waelchli R; Bollbuck B; Bruns C; Buhl T; Eder J; Feifel R; Hersperger R; Janser P; Revesz L; Zerwes HG; Schlapbach A
Bioorg Med Chem Lett; 2006 Jan; 16(1):108-12. PubMed ID: 16236504
[TBL] [Abstract][Full Text] [Related]
20. A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors.
Sperandio da Silva GM; Sant'Anna CM; Barreiro EJ
Bioorg Med Chem; 2004 Jun; 12(12):3159-66. PubMed ID: 15158784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
